CytRx

CYTR OTCMKTS
0.3600
+0.0200
+5.88%
Closed 15:59 06/20 EDT
Open
0.3230
Prev Close
0.3400
High
0.3750
Low
0.3230
Volume
63.23K
Avg Vol (3M)
201.36K
52 Week High
1.300
52 Week Low
0.2550
% Turnover
0.19%
Market Cap
12.11M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers CytRx CYTR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
MORE >

Recently

Name
Price
%Change